07:00 , Apr 13, 2015 |  BC Week In Review  |  Clinical News

Antineoplastons: Phase II data

A U.S. Phase II trial in 19 evaluable patients with newly diagnosed anaplastic astrocytoma showed that ANP every 4 hours led to a complete response rate of 21% and a stable disease rate of 26%....
07:00 , Jun 1, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons: Phase II data

Data from a Japanese Phase II trial in 65 MCRC patients who had undergone curative resection of hepatic metastases showed that Antineoplastons (ANP) therapy in combination with 5-fluorouracil (5-FU) produced an overall 5-year survival rate...
07:00 , May 18, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons: Phase II data

Data from 80 evaluable patients in a Phase II trial showed that IV antineoplastons therapy resulted in complete or partial responses in 32% of patients and stable disease in 43%. Overall survival was 36% at...
07:00 , May 11, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons: Final Phase II data

Final data from an open-label, U.S. Phase II trial in 16 children showed that IV antineoplastons therapy met the primary endpoint of achieving an objective response in at least 10% of patients (5 patients or...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Clinical News

Antineoplastons regulatory update

Burzynski Research received an SPA from FDA for a Phase III trial to evaluate antineoplaston in combination with radiotherapy to treat newly-diagnosed diffuse intrinsic brainstem glioma in pediatric patients. The therapy combines injectable Atengenal (antineoplaston...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

Antineoplaston therapy regulatory update

FDA granted Orphan Drug designation for Burzynski's antineoplaston therapy to treat gliomas. The therapy, which combines injectable Atengenal (antineoplaston A10) and injectable Astugenal (antineoplaston AS2-1), a pair of synthetic peptides that inhibit neoplastic cell growth,...
08:00 , Dec 8, 2008 |  BC Week In Review  |  Clinical News

Antineoplaston therapy: Phase II data

Data from 20 evaluable patients in an open-label U.S. Phase II trial, showed that antineoplastons therapy resulted in complete disappearance of tumors in 5 patients, while 8 patients had stable disease. The therapy, which comprises...